Navigating the new horizon of Natural Killer T (NKT) cell therapies to fight against cancers and autoimmune disorders
2020 New Cancer Cases Globally
0
M
2040 Proj. New Cancer Cases Globally
0
M
2020 Cancer Deaths Globally
0
M
2040 Proj. Cancer Deaths Globally
0
M
Our Mission
is to address the patient unmet needs with our novel off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for the treatment of cancers and other immune-mediated disorders.
Tinkeso Therapeutics, Inc, formally Akeso Therapeutics, is an early-stage biotech company based in Valhalla, NY.
Our pipeline covers both native and engineered NKT cell therapies. Our lead asset, IMK-101, is an engineered invariant NKT (iNKT) cell therapy targeting several types of leukemia.